Difficulty: Medium
Average Score: 67%
Practice
Lab results reveal that 82-year-old male with type 2 diabetes has a HgbA1C of 10.9%. He is presently taking glipizide (Glucotrol). In addition to his type 2 diabetes, he has renal insufficiency and moderate cardiac ischemi Which of the following interventions is most appropriate for management of the patientÔÇÖs diabetes?
Correct answer
A
Rationale
The most appropriate intervention for managing the patient's diabetes in this scenario is to discontinue Glucotrol and start insulin (Option A). This decision is based on several factors specific to the patient's condition and the pharmacological properties of the medications involved.
Firstly, the patient's HgbA1C level of 10.9% indicates poor glycemic control, which necessitates a more effective and reliable treatment approach than oral antidiabetic agents like glipizide. Insulin therapy provides precise control over blood glucose levels and is particularly beneficial in patients with renal insufficiency and cardiac issues, as it does not rely on renal clearance for metabolism and excretion.
Discontinuing Glucotrol is crucial due to the risk of hypoglycemia associated with sulfonylureas, especially in older adults with renal impairment. Additionally, the patient's renal insufficiency may limit the effectiveness of oral antidiabetic agents like glipizide.
The other options (B, C, D) are not as suitable in this case due to various reasons. Adding sitagliptin (Januvia) (Option B) may not provide sufficient glycemic control given the patient's high HgbA1C level. Adding metformin (Glucophage) (Option C) is contraindicated in patients with renal insufficiency due to the risk of lactic acidosis. Adding pioglitazone (Actos) (Option D) is not recommended in patients with moderate cardiac ischemia due to potential cardiovascular risks associated with this medication.
From an educational perspective, understanding the rationale behind choosing the appropriate antidiabetic therapy based on individual patient characteristics is vital for safe and effective pharmacological management. This case highlights the importance of considering comorbidities, renal function, and cardiovascular risk factors when selecting the most suitable treatment option for patients with diabetes.
Firstly, the patient's HgbA1C level of 10.9% indicates poor glycemic control, which necessitates a more effective and reliable treatment approach than oral antidiabetic agents like glipizide. Insulin therapy provides precise control over blood glucose levels and is particularly beneficial in patients with renal insufficiency and cardiac issues, as it does not rely on renal clearance for metabolism and excretion.
Discontinuing Glucotrol is crucial due to the risk of hypoglycemia associated with sulfonylureas, especially in older adults with renal impairment. Additionally, the patient's renal insufficiency may limit the effectiveness of oral antidiabetic agents like glipizide.
The other options (B, C, D) are not as suitable in this case due to various reasons. Adding sitagliptin (Januvia) (Option B) may not provide sufficient glycemic control given the patient's high HgbA1C level. Adding metformin (Glucophage) (Option C) is contraindicated in patients with renal insufficiency due to the risk of lactic acidosis. Adding pioglitazone (Actos) (Option D) is not recommended in patients with moderate cardiac ischemia due to potential cardiovascular risks associated with this medication.
From an educational perspective, understanding the rationale behind choosing the appropriate antidiabetic therapy based on individual patient characteristics is vital for safe and effective pharmacological management. This case highlights the importance of considering comorbidities, renal function, and cardiovascular risk factors when selecting the most suitable treatment option for patients with diabetes.